Institutionen för medicinska vetenskaper

Utvalda artiklar Hilpi Rautelin

Kampmann C, Dicksved J, Engstrand L, Rautelin H. Composition of human feacal microbiota in resistance to Campylobacter infection. Clin Microbiol Infect 2016; 22: 61.e1-.e8

Skarp CPA, Hänninen M-L, Rautelin HIK. Campylobacteriosis: the role of poultry meat. (Review) Clin Microbiol Infect 2016; 22: 103-109.

Skarp CP, Akinrinade O, Nilsson AJ, Ellström P, Myllykangas S, Rautelin H. Comparative genomics and genome biology of invasive Campylobacter jejuni. Sci Rep 2015; 5:17300

Dicksved J, Ellström P, Engstrand L, Rautelin H. Susceptibility to  Campylobacter infection is associated with the species composition of the human fecal microbiota. Mbio 2014; 5: e01212-14.

Feodoroff B, de Haan CP, Ellström P, Sarna S, Hänninen ML, Rautelin H. Clonal distribution and virulence of Campylobacter jejuni isolates in blood. Emerg Infect Dis 2013; 19: 1653-1655.

Ellström P, Feodoroff B, Hänninen ML, Rautelin H. Lipooligosaccharide locus class of Campylobacter jejuni: sialylation not needed for invasive infection. Clin Microbiol Infect 2014; 20: 524-529.

Utvalda artiklar Johan Lennerstrand

Kokkula C, Palanisamy N, Ericstam M, Lennerstrand J. SYBR Green II Dye-Based Real-Time Assay for Measuring Inhibitor Activity Against HIV-1 Reverse Transcriptase. Mol Biotechnol. 2016 Jul 4.

Palanisamy N, Lennerstrand J. Biophysical studies on HCV 1a NS3/4A protease and its catalytic triad in wild type and mutants by in silico approach. Interdiscip Sci Comput Life Sci, 2016, June 16.

Miller V, Harrington P, Howe A, Kieffer T, Lennerstrand J, Lenz O, Lontok E, McPhee F, Mo H, Parkin N, Pilot-Matias T, and. Reply to Halfon et al.; Hepatitis C genotype 4R resistance associated polymorphisms: the Achilles heel of NS5A inhibitors? Hepatology.2016 Apr 26

Bergfors A, Leenheer D, Bergkvist A, Ameur A and Lennerstrand J. Analysis of Hepatitis C NS5A resistance associated polymorphisms using ultra deep single molecule real time (SMRT) sequencing. Antiviral Research, 2016 Feb;126:81-9.

Lontok E, Harrington P, Howe A, Kieffer T, Lennerstrand J, Lenz O, McPhee F, Mo H, Parkin N, Pilot-Matias T, and Miller V. Hepatitis C Virus Drug Resistance Associated Substitutions: State of the Art Summary. Hepatology.2015 Nov;62(5):1623-32.

Lindstrom I, Kjellin M, Palanisamy N, Bondeson K, Wesslen L, Lannergård A, Lennerstrand J. Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with Hepatitis C virus genotype 1a and 3a in Sweden. Infectious Disease, 2015 Aug;47(8):555-62.

Danielsson A, Palanisamy N, Golbob S, Yin H, Blomberg J, Hedlund J, Sylvan S, Lennerstrand J. Transmission of hepatitis C virus among intravenous drug users in the Uppsala region of Sweden. 2014. Infect. Ecol. Epidemiol. Jan 15;4

Palanisamy N, Danielsson A, Kokkula C, Yin H, Bondeson K, Wesslén L, Duberg AS, Lennerstrand J.

Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a. Antiviral Research, 2013 May 3;99(1):12-17

Stålhandske P, Wang L, Westberg S, Euler HV, Groth E, Gustafsson SA, Eriksson S, Lennerstrand J. Homogeneous assay for real-time and simultaneous detection of thymidine kinase 1 and deoxycytidine kinase activities. Analytical Biochemistry 2013 Jan 15;432(2):155-64.